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Avascular necrosis of the hip and diffuse
idiopathic skeletal hyperostosis during long-
term isotretinoin treatment of epidermolytic
ichthyosis due to a novel deletion mutation in
KRT10
DOI: 10.1111/bjd.13049
DEAR EDITOR, Epidermolytic ichthyosis (EI; OMIM 113800),
previously termed bullous congenital ichthyosiform erythro-
derma or epidermolytic hyperkeratosis, is a clinically heteroge-
neous disorder of keratinization. It is usually characterized by
severe neonatal erythroderma, blistering and fragile skin, with
the subsequent development of hyperkeratosis, predominantly
in flexural areas. It is caused by mutations in either the KRT1
or KRT10 genes encoding the suprabasal keratins K1 and K10,
respectively.1 Mutations are usually missense substitutions in
the highly conserved alpha-helical rod domains of these kera-
tins, which play a critical role in filament formation.2 We
report a multigeneration kindred with EI due to a novel muta-
tion in KRT10.
The proband was a 32-year-old woman from Shetland.
She presented with widespread fine scale and erythema of
her trunk and limbs, with a history of scaling and redness
since birth but no blistering, erosions or collodion mem-
brane reported. Clinical examination revealed widespread ich-
thyosis and erythema affecting the trunk and all four limbs,
with more significant hyperkeratosis at the elbows, knees
and ankles but relative sparing of palmoplantar skin (Fig. 1).
Her father, uncle and grandmother were affected, and four
further generations were reported to be affected. She had
been maintained on oral isotretinoin 20–40 mg daily, thus
modifying the clinical appearance, from the age of 13 years,
but had recently developed lower back and hip pain. Radio-
graphs of the lumbar spine and left hip demonstrated bridg-
ing osteophytes form T11 to L1, suggestive of diffuse
idiopathic skeletal hyperostosis (DISH), and magnetic reso-
nance imaging confirmed the presence of avascular necrosis
of the left hip. This was successfully treated with core
decompression of the left hip with improvement in the
patient’s pain.
A biopsy of affected skin of the upper limb was obtained
from the proband and processed for light microscopy by stan-
dard methods. Structural analysis demonstrated acanthosis,
marked overlying hyperkeratosis and vacuolar change of the
upper epidermal cells with prominent clumping of keratohya-
line granules.
Following informed consent, genomic DNA samples were
obtained from blood samples from the proband and her
father. Mutation analysis of the coding regions and splice sites
of the KRT1 and KRT10 genes was performed by standard poly-
merase chain reaction (PCR) and Sanger sequencing methods
using specific primers. Sequence analysis of KRT10 revealed a
previously unreported heterozygous deletion of 167 base pairs
extending from intron 5 into exon 6 (c.1156–79_1243del),
abolishing the intron 5 acceptor splice site (Fig. 2). This
mutation was also present in the proband’s affected father.
(a)
(b)
(c)
Fig 1. Family with epidermolytic ichthyosis. (a) Clinical picture of
the proband: hyperkeratosis of nonplantar sites modified by oral
retinoid therapy; (b, c) photographs of her father.
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RNA was obtained from the proband’s skin biopsy. Follow-
ing reverse transcription by standard methods, reverse-trans-
criptase PCR was performed using primers flanking the
deletion on exons 5 and 6 of KRT10. RNA analysis demon-
strated that the KRT10 c.1156–79_1243del deletion activates a
cryptic splice site 96 base pairs downstream from the consen-
sus intron 5–exon 6 splice site, resulting in an in-frame dele-
tion of 32 amino acids, p.Lys386_Gln417, in the K10 protein.
This truncated K10 protein, lacking the conserved helix termi-
nation motif, is likely to exert a dominant–negative effect on
K1/K10 filament formation.
The keratin intermediate filament network is the main
stress-bearing structure within the cytoplasm of epithelial
cells. EI is caused by mutations in the keratin genes KRT1 and
KRT10, which confer structural integrity to suprabasal kerati-
nocytes, with most reported mutations being heterozygous
missense mutations.3 Approximately half of all cases of EI
occur sporadically due to a spontaneous mutation.2 In inher-
ited cases of EI, it is inherited mostly in a dominant mode,
as in this pedigree, although recessive inheritance has been
reported.4 Severe EI has been associated with mutations in
the highly conserved helix boundary motifs, the helix initia-
tion and termination peptides and the nonhelical H1 domain
of K1 and K10.3 Mutations in the L1–2 linker of K1 or out-
side the helix boundary motifs, similar to those seen in mild
epidermolysis bullosa simplex, have been described.5 A small
number of insertion/deletion mutations and splice-site defects
leading to larger in-frame deletions or rare dinucleotide alter-
ations in KRT10, leading to substitution of two adjacent
amino acids, have been described.6 Genotype–phenotype cor-
relations in EI are very complex, and it is suggested that both
the position of the mutation within K1 or K10 and the nat-
ure of the amino acid substitution specifically influence the
phenotypic expression of the disease.7 Systemic retinoids
should be used with caution in EI due to a risk of increased
fragility and a tendency to blistering, although both topical
and oral retinoids are thought to be more effective in those
patients with EI with K10 mutations compared with K1. It is
postulated that this may be due to the ability of patients with
K10 mutations to tolerate better the downregulation of K2
caused by retinoids.8
To our knowledge, avascular necrosis of the femoral head
has not previously been reported secondary to isotretinoin,
and it is unclear whether this contributed to the findings in
the proband. Avascular necrosis of the femoral head occurs
due to interruption of the microcirculation of the femoral
head resulting in ischaemia, and may occur spontaneously or
in relation to treatment with glucocorticoids, hypertension,
sickle cell disease, trauma or other causes. Avascular necrosis
of the hip has been reported with retinoids (all-trans-retinoic
acid) used to treat haematological conditions; however,
affected cases have often received concomitant glucocortic-
oids.9 The long-term effects of oral retinoids remain under
debate; however, experience of exposure to isotretinoin at this
dose and for this length of time has been reported in the liter-
ature only rarely in comparison with other retinoids.10 Previ-
ously reported skeletal abnormalities with retinoid therapy
include periosteal thickening, premature epiphyseal closure in
children, osteoporosis, extraspinal tendon and ligament calcifi-
cation, osteophytes and bony bridges between vertebrae as in
the proband, in addition to DISH characterized by anterior
spinal ligament calcification. However, there are few prospec-
tive studies on the skeletal effects of long-term systemic reti-
noids, and many of the bony changes reported are also
prevalent in the general population. This finding adds to the
evidence that KRT10 mutations are the principal cause of auto-
somal dominant EI with palmoplantar sparing. It also high-
lights the possible side-effects of long-term oral retinoid
treatment in these inherited conditions.
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Fig 2. DNA sequencing of the KRT10 gene in the proband. Sequencing reveals a novel heterozygous deletion extending from intron 5 into exon 6
(K10 c.1156–79_1243del), abolishing the exon 6 acceptor splice site resulting in a shorter aberrant keratin 10 (K10) protein lacking a sequence
motif critically important for keratin filament assembly. The mutation was present in the proband’s affected father but not in unaffected control
samples.
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Short- to intermediate-term follow-up in
patients treated with the combination of
311-nm ultraviolet B phototherapy and
biological agents
DOI: 10.1111/bjd.12992
DEAR EDITOR, Previous studies1–4 have indicated that ultraviolet
(UV) B phototherapy may increase the therapeutic response to
biologics (see also citations in refs 1–4). Most recently, Cal-
zavara-Pinton et al. reported that combined treatment with
311-nm UVB and etanercept had a synergistic effect for clear-
ing chronic plaque-type psoriasis that was previously un-
responsive to either form of monotherapy alone.5 However,
UVB phototherapy is potentially carcinogenic (although this
has not yet been shown for 311-nm UVB in humans), and
there are safety concerns, particularly in combination with
biological agents.4 We therefore analysed all available follow-
up data to detect nonmelanoma skin cancer (NMSC) or mela-
noma in patients with psoriasis treated with 311-nm UVB
phototherapy in combination with various biologics in differ-
ent trials at our institution.1–4
From 29 patients with chronic plaque psoriasis who had
been treated by combining 311-nm UVB with at least one
biological agent at our department,1–4 28 (10 women, 18
men) were included in the follow-up analysis. One patient
was excluded from the risk analysis because of a history of mul-
tiple grenz (Bucky) X-ray irradiation-related basal cell carcino-
mas before the start of combination treatment, but was
included in the statistical analysis of therapeutic efficacy
shown in Table 1. One patient, who was discontinued from
the half-body comparison study with ustekinumab4 because of
a circumscribed herpetic eruption on the thigh on the UV-
exposed body half, was excluded from the statistical analysis
Table 1 Results on the efficacy of 311-nm ultraviolet (UV) B plus biologic combination therapy
Biologic, ref./NCT no.
Number
of patients
treated in
a study
Percentage PASI reduction
Week 6 Week 12
UV No UV UV No UV
Etanercept3 5 850 552 907 810
Adalimumab2, NCT00638469 6 835 461 677 512
GolimumabNCT01088698 2 829 693 n.a. n.a.
Ustekinumab4 9 816 541 846 789
Alefacept1 14 726 315 827 637
All biological agents 36a 811 512* 814 687†
Data are mean values calculated from the results of 311-nm UVB half-side comparison studies, previously reported in refs 1–4 and two regis-
tered clinical trials. PASI, Psoriasis Area and Severity Index; n.a., not available. aCertain patients participated in more than one trial; therefore
the total number for treatment with biological agents is higher than the total patient number (i.e. 28). *P = 0003; †P = 00255 by two-
tailed paired Student’s t-test comparing the UV-irradiated body halves vs. the nonirradiated body halves, based on intention to treat as in the
first 6 weeks. Note that a portion of the patients (n = 6) were also treated between weeks 7 and 12 with total-body 311-nm UVB (including
the previously nonirradiated body half).
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